Sanofi sues Eli Lilly for patent infringement

French pharmaceutical giant Sanofi has said it is suing US rival Eli Lilly in an American court for infringing four patents relating to its diabetes treatments.

The lawsuit, lodged in the state of Delaware, was triggered by Eli Lilly's notification last month that it plans to ask the US Food and Drug Administration (FDA) for permission to put a new diabetes treatment on the market.

"Sanofi announced today (Thursday) that it filed a patent infringement suit against Eli Lilly and Company," the French company said in a statement.

Sanofi is seeking to protect its insulin Lantus and insulin pen Lantus SoloStar, which generate a sixth of the company's sales.

Eli Lilly is challenging Sanofi patents listed for Lantus and has stated that it will not launch its own product before the expiry of Sanofi's patent on the drug's active ingredient, which is in force until mid-February 2015, Sanofi said in its statement.

Mark Clark, analyst at Deutsche Bank, said the lengthy legal process begun by Sanofi would probably delay Eli Lilly's launch of the drug to market until at least 2016.

An Eli Lilly spokesman told AFP it was studying the complaint and had no immediate comment.

add to favorites email to friend print save as pdf

Related Stories

China targets Germany's Bayer in drug price probe

Sep 13, 2013

Chinese authorities have visited an office of German pharmaceutical giant Bayer, the company said Friday, making it the latest target in a probe of foreign drug firms over high prices.

US health watchdog rejects Sanofi's MS drug

Dec 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.